Chinese ADC, RNA Therapy Developers Lead May/June Fundraising

Emerging companies including Bliss Biopharmaceutical, Coherent Biopharma and WestGene Biopharma lifted China biotech funding from May to mid-June.

funding
Antibody-drug conjugates and RNA therapies come to fore as promising assets in China • Source: Shutterstock

Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash injections into the hot segments of antibody-drug conjugates (ADCs) and RNA therapies.

ADC developer Bliss Biopharmaceutical (Hangzhou) Co., Ltd revealed on 6 June its Japanese partner Eisai Co., Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia

Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

 
• By 

Biosimilars giant Celltrion tells shareholders there could be multiple opportunities for its business under US President Donald Trump’s latest executive order on drug pricing.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By 

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.